Progression-free survival in patients with chronic myeloid leukemia with a major molecular response may be predicted 2.5 years after diagnosis.

Conferences

Drs Morton Coleman and John P. Leonard summarize the key take-home points presented on lymphoma during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications.
Drs Morton Coleman and Richard R. Furman summarize the key take-home points presented on CLL during Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, and examine their clinical implications.

News

Progression-free survival in patients with chronic myeloid leukemia with a major molecular response may be predicted 2.5 years after diagnosis.
The US Food and Drug Administration has granted expanded approval for a drug to treat adults and children with acute lymphoblastic leukemia.
The US Food and Drug Administration has granted approval for a drug to include treatment of first- and second-line pediatric patients with chronic myeloid leukemia.
Sorafenib treatment before, after, or before and after allogenic hematopoietic stem cell transplantation may improve outcomes for patients with acute myeloid leukemia with FMS-like tyrosine kinase 3-internal tandem duplication.

Quiz

A recently developed model for AML was found to accurately predict which outcome after treatment?
Elevated expression levels of what gene translates to a poor prognosis in acute myeloid leukemia and should be used to guide treatment decisions?

Research in Review

Maintenance therapy with a targeting agent may provide survival benefits beyond first- and second-line chemotherapy in patients with diffuse large B-cell lymphoma, according to an analysis published in PLOS One.
Patients with mantle cell lymphoma benefit from prolonged event-free survival and overall survival when treated with autologous stem cell transplantation and total body irradiation.
Subscribe to Blood Cancer